Domenico Accili

Reprogramming insulin receptor activation with a de novo agonist to overcome severe insulin resistance

This study develops a de novo insulin receptor agonist, RF-409, which effectively treats severe insulin resistance in a mouse model by activating a mutant receptor and improving glucose homeostasis.

Tuning Insulin Receptor Signaling Using De Novo Designed Agonists

This paper designs synthetic insulin receptor agonists that modulate receptor conformation and signaling, showing improved potency and activity in disease mutants.

Fatty Acid Transport Protein-2 (FATP2) Inhibition Enhances Glucose Tolerance through α-Cell-mediated GLP-1 Secretion

This study shows that inhibiting FATP2 improves glucose tolerance via α-cell GLP-1 secretion and β-cell insulin release in diabetic mice.

Chemical induction of gut β-like-cells by combined FoxO1/Notch inhibition as a glucose-lowering treatment for diabetes

The paper shows that a small molecule FoxO1 inhibitor generates gut β-like cells, improving glucose tolerance in diabetes models.

An integrative transcriptional logic model of hepatic insulin resistance

This paper investigates the transcriptional regulation of lipid and glucose metabolic genes in hepatic insulin resistance, finding distinct regulatory patterns and a model for their coexistence in type 2 diabetes.

Cyb5r3 links FoxO1-dependent mitochondrial dysfunction with β-cell failure

This study identifies Cyb5r3 as a mediator of FoxO1-dependent mitochondrial dysfunction in beta-cells, leading to impaired insulin secretion and glucose intolerance.